Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 26, Issue , 2015, Pages v126-v132

  Dummer, R ^a   Hauschild, A ^b   Lindenblatt, N ^a   Pentheroudakis, G ^c   Keilholz, U ^d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DACARBAZINE; IPILIMUMAB; NIVOLUMAB; PEGINTERFERON ALPHA2B; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR;

ARTICLE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER STAGING; CUTANEOUS MELANOMA; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; EPILUMINESCENCE MICROSCOPY; FOLLOW UP; HUMAN; LOW DRUG DOSE; LYMPH NODE DISSECTION; LYMPH NODE IRRADIATION; LYMPH NODE METASTASIS; METASTATIC MELANOMA; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; SKIN BIOPSY; SURVIVAL RATE; ULTRAVIOLET IRRADIATION; MELANOMA; PATHOLOGY;

HUMANS; MELANOMA;

EID: 84941625600     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv297     Document Type: Article

References (54)

1. Hollestein LM, van den Akker SA, Nijsten T et al. Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. Ann Oncol 2012; 23: 524-530.
2. Forsea AM, Del Marmol V, Stratigos A, Geller AC. Melanoma prognosis in Europe: far from equal. Br J Dermatol 2014; 171: 179-182.
3. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011; 29: 257-263.
4. Dummer R, Guggenheim M, Arnold AW et al. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly 2011; 141: w13320.
5. Bono A, Tolomio E, Trincone S et al. Micro-melanoma detection: a clinical study on 206 consecutive cases of pigmented skin lesions with a diameter < or = 3 mm. Br J Dermatol 2006; 155: 570-573.
6. Grob JJ, Bonerandi JJ. The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol 1998; 134: 103-104.
7. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002; 3: 159-165.
8. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
9. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011; 24: 879-897.
10. Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 2014; 9: 239-271.
11. Schoenewolf NL, Bull C, Belloni B et al. Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. Eur J Cancer 2012; 48: 1842-1852.
12. Hirakawa S, Kodama S, Kunstfeld R et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005; 201: 1089-1099.
13. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365: 687-701.
14. Han D, Zager JS, Shyr Y et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol 2013; 31: 4387-4393.
15. Morton DL, Thompson JF, Cochran AJ et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355: 1307-1317.
16. Eggermont AM, Suciu S, Testori A et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012; 48: 218-225.
17. Kirkwood JM, Ibrahim JG, Sondak VK et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 2444-2458.
18. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102: 493-501.
19. Eggermont AM, Suciu S, Santinami M et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117-126.
20. Eggermont AM, Suciu S, Testori A et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 2012; 30: 3810-3818.
21. Eggermont AM, Chiarion-Sileni V, Grob JJ et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet 2015; 16: 522-530.
22. Kleeberg UR, Suciu S, Brocker EB et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004; 40: 390-402.
23. Oberholzer PA, Kee D, Dziunycz P et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30: 316-321.
24. Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366: 207-215.
25. Zimmer L, Hillen U, Livingstone E et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012; 30: 2375-2383.
26. Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002; 146: 1042-1046.
27. Burmeister BH, Henderson MA, Ainslie J et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012; 13: 589-597.
28. Hong A, Fogarty G. Role of radiation therapy in cutaneous melanoma. Cancer J 2012; 18: 203-207.
29. Campana LG, Testori A, Mozzillo N, Rossi CR. Treatment of metastatic melanoma with electrochemotherapy. J Surg Oncol 2014; 109: 301-307.
30. Andtbacka RH, Kaufman HL, Collichio F et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015 [Epub ahead of print].
31. Flaherty KT, Hennig M, Lee SJ et al. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol 2014; 15: 297-304.
32. McArthur GA, Chapman PB, Robert C et al. Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15: 323-332.
33. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
34. Guo J, Si L, Kong Y, Flaherty KT et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29: 2904-2909.
35. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
36. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
37. Long GV, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877-1888.
38. Robert C, Karaszewska B, Schachter J et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30-39.
39. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330.
40. Ascierto PA, Schadendorf D, Berking C et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, openlabel phase 2 study. Lancet Oncol 2013; 14: 249-256.
41. Larkin J, Ascierto PA, Dréno B et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867-1876.
42. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532.
43. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4-treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375-384.
44. Dummer R, Daud A, Puzanov I et al. A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. J Transl Med 2015; 13(Suppl 1): 05.
45. Robert C, Dummer R, Gutzmer R et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol 2013; 14: 733-740.
46. Long GV, Trefzer U, Davies MA et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 1087-1095.
47. Margolin K, Ernstoff MS, Hamid O et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13: 459-465.
48. Dummer R, Goldinger SM, Turtschi CP et al. Vemurafenib in patients with BRAF (V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 2014; 50: 611-621.
49. Titus-Ernstoff L, Perry AE, Spencer SK et al. Multiple primary melanoma: two-year results from a population-based study. Arch Dermatol 2006; 142: 433-438.
50. Turner RM, Bell KJ, Morton RL et al. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol 2011; 29: 4641-4646.
51. Bastiaannet E, Wobbes T, Hoekstra OS et al. Prospective comparison of [18F] fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol 2009; 27: 4774-4780.
52. Nieweg OE, Kroon BB. The conundrum of follow-up: should it be abandoned? Surg Oncol Clin N Am 2006; 15: 319-330.
53. Beyeler M, Waldispuhl S, Strobel K et al. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein. Dermatology 2006; 213: 187-191.
54. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.